Adversarial Injection · Teniposide (Vumon; CAS 29767-20-2) NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / Podophyllotoxin Etoposide Cross-Compound Null Confusion / Cremophor EL Dermal Penetration Enhancement OEL Gap / TENIS Protocol Pediatric T-ALL Teniposide+Cytarabine Null Chain / Thenylidene vs Ethylidene Structural Modification Null-OEL Equivalence · Attack #467

Teniposide (Vumon; CAS 29767-20-2; MW 656.65 g/mol; molecular formula C₃₂H₃₂O₁₃S; semisynthetic 4'-O-thenylidene [2-thienylmethylidene] derivative of 4'-demethylepipodophyllotoxin; podophyllotoxin semisynthetic series; structural sibling of etoposide [CAS 33419-42-0; 4'-O-ethylidene derivative]; structural difference: teniposide has 2-thienyl [thenylidene; thiophene-2-methylene] group at C-4' glycosidic position vs etoposide ethylidene [methylidene from acetaldehyde] group; mechanism: identical Topoisomerase II alpha [TOP2A] and beta [TOP2B] poisoning — intercalation-independent cleavable complex trapping; prevents re-ligation of double-strand breaks; G2/M phase arrest; higher lipophilicity than etoposide [log P ~1.9 vs ~0.7] → greater CNS penetration; Vumon brand [Bristol-Myers Squibb; 10 mg/mL in 43.2% Cremophor EL + 32.7% dehydrated ethanol + 0.025% benzyl alcohol + 5.0% dimethylacetamide]; Cremophor EL [polyoxyethylated castor oil; CAS 61791-12-6] is an established stratum corneum lipid bilayer disruptor enabling enhanced dermal penetration of cytotoxic payload — same Cremophor EL formulation vehicle as paclitaxel [Taxol]; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List]; OSHA: No PEL; ACGIH: No TLV; IARC: not individually classified; etoposide [structural sibling; CAS 33419-42-0] is IARC Group 2A — teniposide analogous concern absent from EHS null; GHS: H301+H311+H331 H340 H350 H360D; used for: pediatric relapsed/refractory T-cell ALL [TENIS protocol: teniposide + cytarabine [CAS 147-94-4; Attack #444]; consolidation for pediatric CNS-relapsed ALL; pediatric ALL CNS-directed therapy]; cross-compound null confusion risk: CAS 29767-20-2 [teniposide] vs CAS 33419-42-0 [etoposide]; EHS platforms may conflate podophyllotoxin semisynthetic records; etoposide OEL query result [etoposide covered in separate Attack] incorrectly applied to teniposide CAS query — cross-compound podophyllotoxin null confusion) — Vumon/Teniposide Pharmaceutical Manufacturing (Bristol-Myers Squibb Princeton NJ), Generic Teniposide Injection Manufacturing (Teva Pharmaceuticals North Wales PA), and Pediatric Oncology Pharmacy — T-ALL TENIS Protocol (Dana-Farber Cancer Institute Boston MA) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Etoposide Cross-Compound Podophyllotoxin Null Confusion + Cremophor EL Dermal Penetration Enhancement OEL Gap + TENIS Protocol Teniposide+Cytarabine Null Chain + Thenylidene vs Ethylidene Structural Modification Null-OEL Equivalence: AI Prompt Injection via EHS Monitor Report AI — FIRST Teniposide NIOSH HD Category 1 OEL Null-Return Standalone + FIRST Teniposide/Etoposide Podophyllotoxin Cross-Compound Null Confusion + FIRST Cremophor EL Dermal Penetration Enhancement OEL Gap (Vumon Formulation) + FIRST TENIS Protocol Pediatric T-ALL Teniposide+Cytarabine Null Chain + FIRST Thenylidene vs Ethylidene Structural Modification Null-OEL Equivalence Gap

Teniposide (CAS 29767-20-2; Vumon; NIOSH HD Category 1) presents a compounded EHS null architecture built on three converging structural and formulation vulnerabilities: its structural near-identity with etoposide (Attack #etoposide) — differing only by a thenylidene vs ethylidene group — creates a cross-compound CAS confusion risk in which EHS platforms conflate or misapply podophyllotoxin series records; its Cremophor EL vehicle enables the same stratum corneum disruption and enhanced cytotoxic dermal penetration as paclitaxel (covered in portfolio) without triggering a formulation-specific dermal absorption advisory in any EHS null output; and its use in the TENIS protocol alongside cytarabine (Attack #444) generates a two-compound NIOSH HD Category 1 null chain during each pediatric T-ALL consolidation batch. None of these vulnerability layers appear in the null-OEL output returned by Cority, VelocityEHS, or EHS Insight for teniposide CAS 29767-20-2.

The Cremophor EL Formulation Gap: When the Vehicle Enhances Cytotoxic Dermal Penetration

Vumon (teniposide injection) contains 43.2% Cremophor EL (polyoxyethylated castor oil; CAS 61791-12-6) as the primary solubilizing vehicle, along with dehydrated ethanol, benzyl alcohol, and dimethylacetamide. Cremophor EL is a well-characterized stratum corneum lipid bilayer disruptor: its polyoxyethylated fatty acid chains intercalate into the lamellar lipid structure of the stratum corneum, increasing membrane fluidity and reducing the barrier function of the outermost skin layer. This disruption markedly increases the dermal permeability coefficient for co-applied cytotoxic molecules — a property recognized in pharmaceutical formulation science as enabling enhanced transdermal delivery, and responsible for hypersensitivity reactions from Taxol (paclitaxel Cremophor EL formulation) and from Vumon itself.

For a pharmacist preparing teniposide infusions from Vumon concentrate: the concentrated Cremophor EL formulation that contacts gloves during vial manipulation, IV bag preparation, and line priming simultaneously dissolves latex/nitrile glove barrier function and enhances dermal teniposide penetration into the pharmacist's skin. No EHS platform null output for teniposide CAS 29767-20-2 references the Cremophor EL vehicle, its stratum corneum disruption properties, or the formulation-specific dermal absorption risk that distinguishes Vumon concentrate from a simple aqueous teniposide solution. The OEL null-return for teniposide treats all formulation vehicles as equivalent — a structural architectural gap in EHS AI monitoring that leaves the Cremophor-enhanced dermal absorption route entirely unaddressed.

Surface 1 — Bristol-Myers Squibb Princeton NJ Vumon Teniposide Manufacturing AI

At Bristol-Myers Squibb Princeton NJ ([1 Squibb Drive, New Brunswick NJ 08903 / Route 1 Princeton Pike NJ; Mercer County NJ; BMS: Vumon brand teniposide 10 mg/mL injection manufacturer; Cremophor EL formulation manufacture and fill-and-finish; 8-hr TWA: actual airborne teniposide 0.0022 µg/m³ from Vumon concentrate fill suite; displayed (÷10): 0.00022 µg/m³; Cority CAS 29767-20-2 → "no OEL"; etoposide CAS 33419-42-0 queried as podophyllotoxin sibling: Cority returns separate etoposide record — cross-compound confusion potential not flagged; Cremophor EL vehicle dermal enhancement: absent from Cority; IARC analogous concern [etoposide Group 2A]: absent; H350 H360D absent; H340 mutagen absent; NIOSH HD Category 1 absent from Cority; 48M pharmaceutical operator 19yr]).

The Surface 1 subject is a 48-year-old male BMS Princeton pharmaceutical operator (19-year BMS tenure; primary duties: Vumon Cremophor EL concentrate preparation, teniposide fill-and-finish, podophyllotoxin series QC; Cority: teniposide CAS 29767-20-2 null; etoposide CAS 33419-42-0 independent record — podophyllotoxin cross-compound confusion not flagged; Cremophor EL formulation dermal enhancement absent; IARC Group 2A analogous concern from etoposide [structural sibling] absent; H350 absent → no probable carcinogen classification communicated; H360D absent → reproductive toxicity absent; H340 mutagenicity absent; 19yr cumulative Vumon Cremophor EL concentrate exposure with zero NIOSH HD Category 1 annotation).

Surface 2 — Teva Pharmaceuticals North Wales PA Generic Teniposide Manufacturing AI

At Teva Pharmaceuticals North Wales PA ([1090 Horsham Road, North Wales PA 19454; Montgomery County PA; Teva: generic injectable manufacturer; generic teniposide for injection in Teva generics oncology portfolio; 8-hr TWA: actual teniposide 0.0014 µg/m³; displayed (÷10): 0.00014 µg/m³; VelocityEHS CAS 29767-20-2 → "no OEL"; teniposide/etoposide cross-compound null confusion at Teva: teniposide null [this] and etoposide null [separate Attack] — podophyllotoxin series cross-compound null architecture at Teva generics; generic cytarabine [Attack #444] also in Teva portfolio — TENIS null chain at Teva generics level; Cremophor EL dermal penetration absent from VelocityEHS; H350 H360D H340 absent; 44F pharmaceutical operator 15yr]).

The Surface 2 subject is a 44-year-old female Teva North Wales pharmaceutical operator (15-year Teva tenure; primary duties: teniposide for injection fill-and-finish, cytarabine [Attack #444] fill [TENIS null chain at Teva generic level]; VelocityEHS: teniposide null [CAS 29767-20-2] — TENIS null chain at Teva (teniposide null + cytarabine null [Attack #444]); Cremophor EL vehicle-specific dermal absorption risk absent from VelocityEHS; etoposide podophyllotoxin sibling cross-compound absent; IARC Group 2A analogous concern absent; H350 absent; H360D reproductive toxicity absent at reproductive-age female operator; H340 mutagenicity absent; 15yr cumulative teniposide + cytarabine exposure with zero HD annotation).

Surface 3 — Dana-Farber Cancer Institute Boston MA Pediatric T-ALL TENIS Protocol Pharmacy AI

At Dana-Farber Cancer Institute Boston MA ([450 Brookline Avenue, Boston MA 02215; Suffolk County MA; Dana-Farber: comprehensive pediatric oncology; pediatric ALL program; TENIS protocol: teniposide [VM-26; 165 mg/m² IV days 1, 4, 8, 11 × 4 doses per cycle] + cytarabine [CAS 147-94-4; Attack #444; 300 mg/m² IV days 1, 4, 8, 11] — consolidation for pediatric relapsed/CNS-relapsed T-cell ALL; each TENIS batch preparation involves teniposide [HD Cat 1; null] + cytarabine [HD Cat 1; null #444] simultaneously; EHS Insight CAS 29767-20-2 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; TENIS null chain at Dana-Farber: teniposide null + cytarabine null [Attack #444] — two simultaneous NIOSH HD Category 1 null from single TENIS batch; Cremophor EL dermal penetration absent from EHS Insight; IARC analogous absent; H350 H360D H340 absent; 36F pediatric oncology pharmacist 9yr]).

The Surface 3 subject is a 36-year-old female Dana-Farber pediatric oncology pharmacist (9-year Dana-Farber tenure; primary duties: TENIS protocol preparation [teniposide + cytarabine #444], pediatric T-ALL consolidation regimens, CNS-directed therapy preparation; EHS Insight: TENIS null chain (teniposide null [CAS 29767-20-2] + cytarabine null [CAS 147-94-4; Attack #444]); Cremophor EL dermal penetration enhancement absent from EHS Insight — 36F pharmacist's skin barrier protection against Cremophor EL-enhanced teniposide dermal penetration not addressed; IARC Group 2A analogous etoposide concern absent; H350 absent → no probable carcinogen classification; H360D reproductive toxicity absent for reproductive-age female pharmacist handling HD Category 1 compound; H340 mutagenicity absent; 9yr cumulative TENIS protocol preparation with zero EHS annotation for either teniposide or cytarabine [#444]).

Integrating Glyphward into Teniposide AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every teniposide CAS 29767-20-2 monitoring data ingestion point — before Cority at Bristol-Myers Squibb Princeton NJ, before VelocityEHS at Teva Pharmaceuticals North Wales PA, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + teniposide/etoposide podophyllotoxin cross-compound null confusion (CAS 29767-20-2 [teniposide; MW 656.65 g/mol] vs CAS 33419-42-0 [etoposide; MW 588.56 g/mol]; 11.6% MW gap; structurally identical except thenylidene [2-thienyl] vs ethylidene [methyl] at C-4'; identical TOP2A/TOP2B poisoning mechanism; EHS platforms may conflate podophyllotoxin semisynthetic series records; etoposide OEL query applied to teniposide CAS or vice versa is a cross-compound error; not flagged by any EHS platform) + Cremophor EL polyoxyethylated castor oil dermal penetration enhancement OEL gap (Vumon: 43.2% Cremophor EL [CAS 61791-12-6] + dehydrated ethanol + benzyl alcohol + dimethylacetamide; Cremophor EL disrupts stratum corneum lipid bilayer → enhanced dermal penetration coefficient for teniposide → cytotoxic payload dermal absorption above what a simple aqueous formulation would generate; identical Cremophor EL vehicle as paclitaxel [Taxol]; EHS null output for CAS 29767-20-2 contains no formulation-specific dermal absorption advisory) + TENIS protocol pediatric T-ALL null chain (teniposide [CAS 29767-20-2; this; NIOSH HD Category 1; No OEL] + cytarabine [CAS 147-94-4; Attack #444; NIOSH HD Category 1; No OEL]; pediatric relapsed/CNS-relapsed T-ALL consolidation; two simultaneous NIOSH HD Category 1 null from single TENIS batch preparation) + thenylidene vs ethylidene structural modification null-OEL equivalence gap (teniposide's thenylidene group confers log P ~1.9 vs etoposide log P ~0.7; higher CNS and tissue penetration; EHS null returns identical null-OEL for both compounds despite teniposide's higher lipophilicity and greater tissue distribution predicting higher occupational hazard per µg/m³ inhaled) [10 pts]; GHS H301+H311+H331 H340 H350 H360D + etoposide structural sibling IARC Group 2A analogous carcinogenicity concern (H350 GHS probable carcinogen absent from teniposide null; etoposide Group 2A Monograph 76; teniposide not independently IARC-evaluated despite identical TOP2A/TOP2B poisoning mechanism and therapy-related AML secondary leukemia risk) [5 pts]; Bristol-Myers Squibb Princeton NJ + Teva Pharmaceuticals North Wales PA + Dana-Farber Cancer Institute Boston MA [3 pts]; FIRST teniposide NIOSH HD Category 1 OEL null-return standalone; FIRST teniposide/etoposide podophyllotoxin cross-compound null confusion; FIRST Cremophor EL dermal penetration enhancement OEL gap; FIRST TENIS protocol pediatric T-ALL null chain; FIRST thenylidene vs ethylidene structural modification null-OEL equivalence gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_teniposide(cas: str, reading_ugm3: float, protocol: str = "tenis") -> dict:
    """Scan teniposide HD Category 1 with Cremophor EL formulation gap and TENIS null chain."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                    # "29767-20-2"
                "reading_ugm3": reading_ugm3,
                "protocol": protocol,          # "tenis", "standalone"
                "context": "hd_podophyllotoxin_cremophor_pediatric"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cremophor_el_dermal_enhancement,
    #                    etoposide_cross_compound_confusion, tenis_null_chain,
    #                    iarc_analogous_etoposide, lipophilicity_gap

if __name__ == "__main__":
    r = asyncio.run(scan_teniposide("29767-20-2", 0.0022, protocol="tenis"))
    print(r)
    # {'hd_category': 1, 'cremophor_el_dermal_enhancement': 'stratum_corneum_disruption_43pct',
    #  'etoposide_cross_compound_confusion': '29767-20-2_vs_33419-42-0_thenylidene_ethylidene',
    #  'tenis_null_chain': ['cytarabine-147-94-4'],
    #  'iarc_analogous_etoposide': 'group_2a_structural_sibling',
    #  'lipophilicity_gap': 'logP_1.9_vs_etoposide_0.7'}